Global InformationDiacerein information
 | |
 | |
| Clinical data | |
|---|---|
| Other names | Diacetylrhein; Diacerhein; 2-Anthracenecarboxylic acid, 4,5-bis(acetyloxy)-9,10-dihydro-9,10-dioxo-; 2-Anthroic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-, diacetate; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthroic acid, diacetate |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code |
|
| Pharmacokinetic data | |
| Protein binding | 99% |
| Metabolism | Hepatic: deacetylation to rhein, later glucuronidation and sulfate conjugation |
| Elimination half-life | 4 to 5 hours |
| Excretion | Renal (30%) |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| PubChem CID |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEMBL |
|
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | 100.033.904 |
| Chemical and physical data | |
| Formula | C19H12O8 |
| Molar mass | 368.297 g·mol−1 |
| 3D model (JSmol) |
|
| Solubility in water | Practically insoluble in water 0.01 mg/mL (20 °C) |
SMILES
| |
InChI
| |
| (verify) | |
Diacerein (INN), also known as diacetylrhein, is a slow-acting medicine of the class anthraquinone used to treat joint diseases such as osteoarthritis (swelling and pain in the joints).[1] It works by inhibiting interleukin-1 beta. An updated 2014 Cochrane review found diacerein had a small beneficial effect on pain.[2] Diacerein-containing medications are registered in some European Union and Asian countries[which?] and included as a treatment option on several international therapeutic guidelines.[which?][citation needed]
- ^ Gouvas H (2011). Use of Sodium Hyaluronate in the treatment of Osteoarthritis. Greece.
{{cite book}}: CS1 maint: location missing publisher (link) - ^ Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moça Trevisani V (February 2014). "Diacerein for osteoarthritis". The Cochrane Database of Systematic Reviews (2): CD005117. doi:10.1002/14651858.CD005117.pub3. PMC 10712695. PMID 24515444.